These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 2975535

  • 21. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
    Itoh K, Tilden AB, Balch CM.
    Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: a preliminary report.
    Nishioka M, Kagawa H, Shirai M, Terada S, Watanabe S.
    Am J Gastroenterol; 1987 May; 82(5):438-42. PubMed ID: 3495171
    [Abstract] [Full Text] [Related]

  • 30. Serial observation of lymphocyte subpopulations and interleukin 2 production of T cells from patients with acute viral hepatitis and chronic active hepatitis.
    Onji M, Kondo H, Ohta Y.
    Hepatogastroenterology; 1988 Feb; 35(1):10-3. PubMed ID: 3129350
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Natural killer activity in patients with acute viral hepatitis.
    Chemello L, Mondelli M, Bortolotti F, Schiavon E, Pontisso P, Alberti A, Rondanelli EG, Realdi G.
    Clin Exp Immunol; 1986 Apr; 64(1):59-64. PubMed ID: 3089650
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F, Pardo N, Peiró M, Bertran E, Amill B, García J, Cubells J, Rueda F.
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [Abstract] [Full Text] [Related]

  • 36. Peripheral-blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C.
    Schupper H, Hayashi P, Scheffel J, Aceituno S, Paglieroni T, Holland PV, Zeldis JB.
    Hepatology; 1993 Nov; 18(5):1055-60. PubMed ID: 7693570
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis.
    Onji M, Kondoh H, Horiike N, Yamaguchi S, Ogawa Y, Kumon I, Ohta Y.
    Gut; 1987 Dec; 28(12):1648-52. PubMed ID: 3501387
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.